New Developments in the Treatment and Management of Psoriasis: Key Considerations for Improving Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation and UCB

Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million of the population in the United States. Psoriasis is a periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumboscaral areas of the body. Psoriasis is a complex disease to manage, but the goal should be a patient-centered treatment that reduces disease burden, improves on quality-of-life, and addresses the risks of systemic complications and comorbid conditions. The under diagnosis and treatment of psoriasis continues to be a serious concern. Once psoriasis is diagnosed through a physical examination and a skin biopsy, treatment of the disease will depend on which type of psoriasis, where it is, and the severity of it. Newer treatments, such as biologics, work by inhibiting different types of cytokines while the early biologics work by inhibiting tumor necrosis (TNF)-alpha, a protein broadly involved in inflammation. Newer biologics are more targeted to the inflammatory pathways involved in psoriasis, which works by blocking two proteins -- interleukin-17 and -23. These newer agents have been shown to be effective in treating psoriasis and could also be safer given their more specific action on the immune system. There are also newer non-biologic systemic treatments for psoriasis and they do not directly inhibit inflammatory cytokines and is thought to have no increased risk of infection; however, it is generally less effective in treating psoriasis. Recent research indicates that both IL-23 and IL-17 play important roles in the development of psoriatic plaques. Treatments that inhibit IL-23 and IL-17 have shown promising data in safety and efficacy in clinical trials of moderate-to-severe psoriasis. Recent breakthroughs, and a better understanding of the pathogenesis of psoriasis, have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis.

Upon completion of this activity, participants will be able to:

  • Describe how to use current guidelines and new clinical evidence to develop an appropriate management plan by examining clinical features and pathogenesis of psoriasis

  • Explore best practices and evidence for accurate screening and diagnosis of patients of psoriasis based on disease severity

  • Examine the efficacy, safety, and utility of appropriate current and novel therapies for psoriasis, including IL-17 and IL-23 inhibitors

  • Develop new strategies to manage challenges, including comorbidities, by utilizing a collaborative treatment approach with other disciplines

  • Examine managed care perspectives and considerations for a multidisciplinary plan by exploring where current and emerging therapeutic agents fit into the evolving treatment paradigm


Faculty: Paul Yamauchi, MD, PhD
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
Adjunct Associate Professor
John Wayne Cancer Institute


Dr. Yamauchi serves as a consultant for AbbVie, Amgen, Janssen, Novartis, Lilly, Sun, Ortho Dermatologics, and UCB. He has received grants/research suport from AbbVie, Amgen, Janssen, Novartis, lilly, Sun, Ortho Dermatologics, Leo, BMS, Dermavant, and UCB. He serves on the speaker's bureau for AbbVie, Amgen, Janssen, Novartis, Lilly, Sun, Ortho Dermatologics, and UCB. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation and UCB

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue